octreotide acetate / Generic mfg. - LARVOL DELTA

177Lu-DOTATATE versus high-dose long-acting octreotide for somatostatin receptor-positive advanced GEP-NETs: A multicenter, randomised, open-label, positive-controlled phase III study (ESMO Asia 2025) - P3 | "177Lu-DOTATATE had an acceptable safety profile in GEP-NETs pts with PFS improvement versus high-dose long-acting octreotide."

Clinical • Late-breaking abstract • Metastases • P3 data • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • SSTR

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. (ASCO-GI 2024) - P3 | "177Lu-DOTATATE significantly prolonged PFS and demonstrated a clinically meaningful ORR, compared with high-dose octreotide LAR, in pts with newly diagnosed advanced G2 and G3 GEP-NETs. Safety was in line with the established profile of 177Lu-DOTATATE. This is the first randomized study to demonstrate efficacy of RLT as 1L treatment in any malignancy and will change clinical practice."

Clinical • Late-breaking abstract • Metastases • P3 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study (ESMO-GI 2024) - P3 | "This preplanned subgroup analysis examined efficacy by NET grade (G2, G3) and NET origin (pancreas, small intestine [SI]). Pts were randomized to receive 4 cycles of 177Lu-DOTATATE (4 × 7.4 GBq) + 30 mg octreotide long-acting release (LAR) every 8 weeks (Q8W) during 177Lu-DOTATATE treatment then Q4W (177Lu-DOTATATE arm; n=151), or 60 mg octreotide LAR Q4W (control arm; n=75). 1L 177Lu-DOTATATE efficacy was maintained across NET grades (G2, G3) and locations (pancreas, SI) and it should be considered a standard of care for this pt population."

Clinical • Metastases • P3 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Hemorrhagic jejunal vascular malformations with loop telangiectasia in Turner's syndrome. (PubMed, Clin Res Hepatol Gastroenterol) - "Still, because loop telangiectasias in Turner's syndrome are tiny, superficial vascular lesions, we attempted a similar treatment to that of angiodysplasia (5), with first-line (argon plasma coagulation) and second-line (long-acting release octreotide), resulting in significant biological improvement in our patient. At 6 months of follow-up after octreotide optimization, no recurrence occurred, hemoglobin rate was 14.1 g/dL with ferritinemia at 16 ng/mL."

Journal • Cardiovascular • Endocrine Disorders • Gastroenterology • Hematological Disorders • Psychiatry • Thrombosis • Turners Syndrome • Women's Health

Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "These findings provide a certain reference for the clinical treatment of ADPKD; however, additional high-quality studies are still needed for further validation. https://www.crd.york.ac.uk/prospero/, identifier CRD420251242104."

Clinical • Journal • Retrospective data • Review • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Lugol's solution for preoperative management of a TSH/GH-secreting pituitary adenoma with suboptimal response to octreotide: a case report. (PubMed, Front Endocrinol (Lausanne)) - "Initial long-acting octreotide treatment was ineffective in controlling hyperthyroidism and was discontinued after 5 months. Despite SSTR2/5 positivity, suboptimal response to octreotide suggests tumor heterogeneity or downstream signaling defects. Preoperative Lugol's solution should be considered when SSAs and methimazole fail."

Journal • Acromegaly • Endocrine Disorders • Oncology • Pain • Pituitary Gland Carcinoma • IGF1 • SSTR2

Individualized treatment strategies for primary hepatic neuroendocrine carcinoma: Two case reports and literature review (A CARE-compliant case report). (PubMed, Medicine (Baltimore)) - "The combination of d-TACE, HAIC, and octreotide may provide a potential downstaging approach for unresectable PHNET, but evidence remains preliminary and hypothesis-generating."

Journal • Review • Endocrine Cancer • Infectious Disease • Neuroendocrine Carcinoma • Oncology • Septic Shock • Solid Tumor

Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "Lu-Dotatate treatment did not significantly improve median overall survival versus high-dose long-acting octreotide. Despite final overall survival not reaching statistical significance, the 11·7 month difference in median overall survival with Lu-Dotatate treatment versus high-dose long-acting octreotide alone might be considered clinically relevant. No new safety signals were reported during long-term follow-up."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Endocrine Cancer • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

Peptide receptor radionuclide therapy (Lu-177 PRRT) in neuroendocrine tumors (NET) over 16 years: Single institution experience. (ASCO-GI 2026) - "Treatment with Lu177-Dotatate PRRT therapy resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced neuroendocrine tumors. PRRT appeared to be effective across all well differentiated NETs regardless of WHO grade, Ki67 rate or primary sites. Results of this small retrospective study from single institution in Saudi Arabia are comparable with the international results."

Clinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Identification of Pancreatic Neuroendocrine Tumor During Evaluation for Severe Valvulopathy in a Patient With a History of Lung Carcinoid Tumor: A Case Report. (PubMed, Cureus) - "The patient underwent aortic valve replacement followed by long-acting octreotide therapy...This case represents an exceptionally rare scenario of pancreatic neuroendocrine tumor in a patient with prior lung carcinoid tumor and raises the critical question of pancreatic metastasis versus a second primary NET in the absence of hereditary syndromes. It underscores the need for heightened vigilance for second primary malignancies (SPMs) and atypical metastatic patterns in patients with a history of NETs and highlights the importance of multidisciplinary evaluation for accurate classification and optimal management."

Journal • Carcinoid Tumor • Cardiovascular • Celiac Disease • Congestive Heart Failure • Endocrine Cancer • Gastrointestinal Neuroendocrine Tumor • Heart Failure • Immunology • Lung Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • NCAM1 • SSTR • SYP

Clinical effectiveness of everolimus plus somatostatin analogues in advanced neuroendocrine tumors: A retrospective real-world study (ESMO Asia 2025) - "Patients received either everolimus alone or in combination with a somatostatin analogue (lanreotide 120 mg Q4W or octreotide LAR 30 mg Q4W). This real-world study suggests that combining everolimus with a somatostatin analogue may improve PFS over monotherapy in advanced NETs, although statistical significance was not reached. The observed trend aligns with clinical trial data and supports the potential benefit of combination therapy in practice. No significant difference was found between lanreotide and octreotide, indicating both agents may be interchangeable when used with everolimus."

Metastases • Real-world • Real-world evidence • Retrospective data • Neuroendocrine Tumor • Oncology • Solid Tumor

Matching-adjusted indirect comparison of surufatinib versus high-dose octreotide LAR in advanced extrapancreatic neuroendocrine tumors (ESMO Asia 2025) - P3 | "This unanchored MAIC suggests surufatinib may improve survival outcomes compared to HD-OCT in advanced epNETs, with a clinically meaningful RMST advantage. The trend aligns with SANET-ep's primary results, supporting surufatinib as a viable therapeutic option."

Metastases • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

FAP-targeted Radio-ligand Therapy in Pancreatic Neuroendocrine Tumor: A Potential Alternative to PRRT. (PubMed, Clin Nucl Med) - "Initial treatment included trans-arterial embolization, long-acting octreotide, followed by chemotherapy...Subsequently, a 99mTc-FAPI-46 scan was conducted, demonstrating favorable uptake in both the liver metastases and the primary tumor, leading to the administration of 177Lu-FAPI-2286 therapy. This case highlights the potential of FAPI as a novel imaging and therapeutic strategy in the management of neuroendocrine tumors."

Journal • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

THE NEED FOR NOVEL THERAPEUTIC DIRECTIONS IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENT CARE. (PubMed, Clin J Am Soc Nephrol) - "At present, the only drugs approved to slow disease progression are the vasopressin V2-receptor antagonist tolvaptan and, in Italy, the somatostatin analogue octreotide long-acting release for the subset of patients with stage 4 chronic kidney disease...These include not only repurposed pharmacological agents, namely sodium-glucose cotransporter-2 inhibitors, metformin, and glucagon-like peptide-1 receptor agonists, but also innovative therapies, as it is the case for a monoclonal antibody against pregnancy-associated plasma protein-A, microRNA-17 inhibitors, and the polycystin-1 correcting agent VX-407. Dietary interventions, such as caloric restriction and ketogenic diets, are being tested in clinical trials as well, and could complement pharmacotherapy to slow disease progression. Moreover, the rapid advancements in the field of gene therapy for ADPKD suggest that this approach, though as yet only explored at experimental level, could be translated into clinical..."

Journal • Autosomal Dominant Polycystic Kidney Disease • Chronic Kidney Disease • Gene Therapies • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease • MIR17 • PKD1

Hoffa's Fat Pad Impingement (HFPI) (clinicaltrials.gov) - P=N/A | N=62 | Not yet recruiting | Sponsor: Boston Children's Hospital

New trial

A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy. (PubMed, Front Cell Dev Biol) - "From August 2019 to October 2020, he received long-acting octreotide and transarterial chemoembolization (TACE), achieving stable disease...In September 2022, oral surufatinib was initiated but paused in September 2023 due to adverse effects...This case demonstrates that everolimus can induce SSTR re-expression in advanced, SSTR-negative pNETs, offering new therapeutic possibilities. The "induction plus re-evaluation" approach could guide personalized treatment strategies in late-stage pNETs, although further studies are needed to validate this approach."

Journal • Gastrointestinal Disorder • Hepatology • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR • SSTR2

SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (clinicaltrials.gov) - P3 | N=332 | Active, not recruiting | Sponsor: Camurus AB | Trial completion date: Dec 2027 ➔ Jul 2028 | Trial primary completion date: Dec 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Neuroendocrine Tumor • Solid Tumor • SSTR

Isolated Right-Sided Heart Failure as the First Manifestation of a Pelvic Neuroendocrine Tumor: A Rare Case of Carcinoid Heart Disease in a female with no prior diagnosis of carcinoid syndrome (AHA 2025) - "She was started on octreotide LAR 20 mg every 4 weeks by Medical Oncology, evaluated by cardiothoracic surgery, and underwent surgical replacement of the aortic, tricuspid, and pulmonic valves...Primary ovarian NETs causing CHD are exceedingly rare, with only isolated case reports. Clinicians should suspect CHD in patients with right-sided heart failure, flushing, or characteristic echocardiographic findings—such as thickened valves and hepatic vein flow reversal—and confirm with elevated 5-HIAA levels."

Clinical • Carcinoid Syndrome • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastrointestinal Disorder • Heart Failure • Neuroendocrine Tumor • Oncology • Pulmonary Disease • Solid Tumor

Routine Turns Rare: Identifying a Cecal Neuroendocrine Tumor During Standard Colonoscopy (ACG 2025) - "The patient was initiated on octreotide LAR and monitored with serial serotonin and chromogranin A levels...Due to the limited number of reported cases in the literature, this case contributes valuable insight into an unusual pattern of metastatic disease. It highlights the importance of maintaining clinical vigilance during routine screening of NET patients, as early identification of atypical metastatic sites facilitates timely diagnosis and comprehensive patient management.Figure: 1 cm circumferential, umbilicated lesion with a central depression located in the cecum.Figure: Biopsy of the lesion was obtained via cold biopsy forceps and sent to pathology."

CNS Disorders • Colon Cancer • Colorectal Cancer • Depression • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Psychiatry • Solid Tumor • SYP

NETTER-3: A phase III study of [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, grade 1 and grade 2 (Ki-67<10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden (ESMO 2025) - P3 | "Trial design NETTER-3 is a phase III, open-label, randomized study of 177 Lu-DOTATATE + octreotide long-acting release (LAR) vs octreotide LAR in pts aged ≥12 years with newly diagnosed (≤6 months), well-differentiated, G1 and G2 (Ki-67 <10%) advanced GEP-NETs and high disease burden (investigator's opinion; guided by tumor bulk, liver involvement, disease spread, and symptoms due to tumor burden or hormone excess). Dosimetry and pharmacokinetics of 177 Lu-DOTATATE will be assessed in a subset of pts. NETTER-3 is being conducted in North America, Europe, and Asia."

Clinical • Metastases • P3 data • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

NETTER-3: [177Lu]Lu-DOTA-TATE in patients with newly diagnosed, Grade 1/2 (Ki-67 <10%) advanced gastroenteropancreatic neuroendocrine tumors and high disease burden (NANETS 2025) - P3 | "METHODS NETTER-3 (NCT06784752) is a Phase III, open-label, randomized study of 177Lu-DOTATATE + octreotide long-acting release (LAR) vs octreotide LAR in patients aged ≥12 years with newly diagnosed (≤6 months), well-differentiated, G1 and G2 (Ki-67 <10%) advanced GEP-NETs and high disease burden (investigator's opinion; guided by tumor bulk, liver involvement, disease spread, and symptoms due to tumor burden or hormone excess). RESULTS NETTER-3 is being conducted in North America, Europe, and Asia. CONCLUSIONS N/A"

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

Hematological Malignancy in a Hypophysectomised Acromegalic Patient Under 4-Year Therapy with Somatostatin Analogues: From a Rib Lump Underlying Bone Plasmatocytoma Features to Multiple Myeloma. (PubMed, Diagnostics (Basel)) - "A 52-year-old male with acromegaly confirmed at 46 (MRI: pituitary macroadenoma of 12 × 11 × 10 mm) underwent hypophysectomy followed by 3 years of octreotide LAR then lanreotide depot. To conclude, what started as a rather typical scenario for an otherwise rare condition, as is acromegaly in the general population (but not so rare for endocrinologists), turned into an unexpected and more severe outcome. Noting this exceptional association, we pinpoint that further research is needed for understanding the dual acromegaly-MM relationship."

Journal • Acromegaly • Bone Marrow Transplantation • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Pain • Plasmacytoma • Transplantation

Medical treatment in acromegaly: a network meta-analysis. (PubMed, Eur J Endocrinol) - "Our findings suggest pasireotide LAR and pegvisomant as the most effective treatments for IGF-1 normalization. Pasireotide LAR was the best treatment for tumor shrinkage, though the evidence base was limited, requiring cautious interpretation. Their potential role as first-line options after surgery requires further research. Clinical decisions should consider cost, safety and patient-specific parameters to optimize outcomes."

Journal • Retrospective data • Acromegaly • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • Rare Diseases • IGF1

Stratification of Biochemical Response to Somatostatin Analogs in Carcinoid Syndrome: Implications for Risk of Carcinoid Heart Disease (NANETS 2025) - "METHODS We retrospectively analyzed patients with carcinoid syndrome initiated on standard-dose somatostatin analog (SA) therapy (lanreotide 120 mg SQ every 4 weeks or octreotide LAR 30 mg IM every 4 weeks)...Patients were included in the TELEHEART study and were randomized to SA + Placebo versus SA + Telotristat Ethyl...This approach enables timely consideration of adjunctive serotonin-lowering therapies for partial responders, who fail to suppress 5-HIAA below 123 ng/mL. Long-term studies can establish the survival impact of this approach."

Oncology

177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial. (PubMed, Ann Oncol) - "XTR008 monotherapy showed superior efficacy versus high-dose long-acting repeatable (LAR) octreotide monotherapy in advanced GEP-NET tumours of all origins in a later-line treatment setting, with manageable safety, supporting its use as a new treatment option."

Journal • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor